GENE ONLINE|News &
Opinion
Blog

2020-12-18| In-DepthSpecial

Coexistence of Thrombophilic Factors and Hemophilia – A Blessing in Disguise?

by GeneOnline
Share To
The most common treatment for hemophilia is a factor replacement therapy, but it comes with challenges like frequent infusions, cost, development of inhibitors, etc. To overcome these limitations, new approaches were explored, such as factors with an extended half-life, inhibition of anticoagulant proteins, and gene therapy.
In normal circumstances, the coexistence of two disorders would enhance distress in an already suffering individual, but what would happen if thrombophilia and hemophilia coexist in an individual? Will they complement each other?

GO Prime with only $1.49 now

LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top